The core argument of the perspective is a reframing of what modern pathogen monitoring needs to achieve. For decades, the dominant measure of progress in detection technology has been analytical sensitivity, the ability to find ever smaller quantities of a target organism in a sample. The authors contend that sensitivity, while still important, is no longer the decisive bottleneck. In their view, the key challenge is no longer simply detecting pathogens with greater sensitivity, but increasing monitoring frequency and expanding surveillance from individual targets to multiple priority pathogens in near real time. In other words, a system that detects one pathogen exquisitely well, once a week, after samples have been shipped to a central laboratory, offers far less protective value than a system that watches many pathogens continuously at the point of concern.

The limitations the authors describe are rooted in the architecture of established microbiological methods rather than in any single technical weakness. Traditional culture-based methods, in which microorganisms are grown on or in nutrient media and identified by their growth characteristics, remain valuable in one crucial respect: they determine whether the microorganisms found in a sample are viable, or alive and capable of reproduction. That information matters enormously for risk assessment, because genetic material from dead organisms does not necessarily indicate an active threat. However, culture methods are slow, often requiring days of incubation, and they are poorly suited to organisms that are difficult to cultivate. They also demand trained personnel, laboratory infrastructure and physical sample transport.

Molecular approaches have transformed pathogen detection over the past several decades. Polymerase chain reaction, or PCR, amplifies specific genetic sequences so that tiny amounts of pathogen DNA or RNA can be detected with high sensitivity. Sequencing technologies go further, allowing detailed characterization of the organisms present in a sample, including the identification of strains, virulence factors and antimicrobial resistance genes. Yet the authors point out that even these powerful molecular tools commonly depend on sample collection, laboratory processing, specialized instruments and subsequent analysis. Each of those steps introduces delay, cost and logistical complexity, which together limit their usefulness for continuous, in situ monitoring, meaning monitoring performed directly at the site of the water body or water system being watched.

To bridge the gap between laboratory-grade analysis and real-time field surveillance, the perspective highlights several emerging technologies that the authors believe could serve as complementary layers in a redesigned monitoring architecture. The first is nanobody-based recognition coupled with fiberoptic sensors. Nanobodies are small, single-domain antibody fragments derived from camelid antibodies that retain antigen-binding capacity while being far smaller, more stable and easier to produce than conventional antibodies. When deployed on the surface of fiberoptic sensors, which convert biological binding events into measurable optical signals, they could enable rapid first-line screening of several predefined pathogens at once, acting as a broad biological tripwire that flags when any of a panel of priority organisms appears in the water.

A second technological layer involves functional nucleic acids, a class of synthetic molecules that includes aptamers and deoxyribozymes. Aptamers are short, single-stranded DNA or RNA sequences that fold into specific three-dimensional shapes capable of binding target molecules with antibody-like affinity and specificity. Deoxyribozymes, or DNA enzymes, are catalytic DNA sequences that can perform chemical reactions, including the sequence-specific cleavage of nucleic acid targets. In the surveillance framework proposed by the authors, these probes could provide a more specific secondary analysis, refining or confirming the preliminary signal generated by the first-line screening step. Because functional nucleic acids are chemically synthesized, they can be selected in the laboratory for virtually any target, are relatively stable, and can be regenerated or integrated into amplification schemes, characteristics that make them attractive for repeated-use sensing surfaces.

The third enabling technology is microfluidics, the engineering discipline concerned with manipulating small volumes of fluids through channels measured in tens or hundreds of micrometers. Microfluidic platforms could automate the sample handling steps that currently consume much of the time and labor in pathogen testing, and they could run many detection reactions in parallel on a single chip. By miniaturizing and integrating filtration, reagent mixing, splitting into multiple channels and signal readout, microfluidics offers a path toward devices that continuously process water samples and test them against an entire panel of pathogen targets without human intervention between sampling and result.

Bringing these components together, the authors sketch an end-to-end framework illustrated in the paper. Automated sampling draws water at regular intervals without an operator on site. Pathogen concentration steps overcome the fundamental dilution problem of environmental monitoring, in which even contaminated water may contain vanishingly few target organisms per liter. Multiplex recognition, the simultaneous interrogation of many targets, is then performed by the nanobody-fiberoptic and functional nucleic acid layers, followed by rapid signal detection, computational data analysis and, crucially, early warning: the automated flagging of results that meet predefined risk thresholds. Importantly, the framework does not discard the classical toolkit. Culture, PCR and sequencing remain available within the system for confirmation and deeper characterization whenever the rapid screening layer raises a flag, preserving the viability information and strain-level detail that only those methods can provide.

The authors are careful to emphasize that practical deployment will require far more than highly sensitive sensors, and this candor is one of the most valuable aspects of the perspective. Environmental water is a hostile medium for analytical instruments. Pathogen concentrations in real water bodies are typically very low, demanding extreme analytical performance. Water matrices are chemically and biologically complex, containing sediments, organic matter, salts and competing microorganisms that can interfere with recognition and signal transduction. Biofouling, the accumulation of microbial films on sensor surfaces, can degrade performance within days. Sensor drift, the gradual change in a device’s response over time, undermines the long-term comparability of measurements. Cross-reactivity, in which a probe binds unintended targets, threatens the specificity that multiplex panels depend on. Calibration across seasons and sites, and simply keeping instruments operating stably over months or years in the field, remain unsolved engineering problems that no amount of laboratory sensitivity can compensate for.

The vision that emerges is therefore not one of replacement but of complementarity. Rather than displacing established laboratory methods, the authors envision biosensors as tools that could shorten response times and strengthen early warning systems, forming a rapid outer ring around the slower but more definitive core of conventional analysis. If the engineering challenges they identify can be met, integrating these technologies into reliable multipathogen surveillance networks may materially improve aquatic biosafety, supporting faster management of waterborne biological risks and, ultimately, safer water for the communities that depend on it. The perspective, published as Li and colleagues’ article in Biocontaminant, offers researchers and water managers a candid map of both the promise and the unfinished work on the road to continuous, multipathogen monitoring.

Subject of Research: Real-time multipathogen biosensing for waterborne pathogen surveillance and aquatic biosafety

Article Title: From single-target tests to real-time multipathogen surveillance for safer water

Article References: From single-target tests to real-time multipathogen surveillance for safer water. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: waterborne pathogens, biosensors, nanobodies, fiberoptic sensors, aptamers, deoxyribozymes, microfluidics, PCR, sequencing, early warning systems, aquatic biosafety, water quality monitoring

The review highlights that waterborne diseases continue to drive enormous mortality, with infectious diarrhea causing nearly 1.2 million deaths each year. While public health gains from decades of improved sanitation have helped, the authors warn that more frequent extreme weather events could erode this progress by stressing water systems and increasing contamination risk.

A key finding is that climate change does not affect all pathogens in uniform ways. Bacteria, viruses, and parasites respond differently to environmental drivers such as temperature, moisture, sunlight exposure, and water availability. This pathogen-specific variability matters for prediction models and for how health agencies prioritize interventions during outbreaks.

Transmission is influenced through multiple pathways. Climate shifts can change whether pathogens survive long enough in aquatic environments, how widely they disperse through infrastructure and food-water contact, and how readily they infect new hosts. Consequently, the same climate event may raise risk for one pathogen while suppressing another.

Flooding remains an obvious hazard because it can breach drinking water infrastructure and transport contaminants into distribution networks. Yet the review emphasizes that drought can also increase risk indirectly by reducing access to safe water, concentrating use into fewer sources, and modifying sanitation practices. Such changes can increase opportunities for fecal contamination and person-to-person spillover.

Temperature generally favors bacterial growth, which can intensify bacterial waterborne outbreaks under warmer conditions. In contrast, some viruses—including norovirus, rotavirus, and adenovirus—may spread more efficiently under cooler, drier conditions. The review notes that this means a warmer world could, for certain viral pathogens, reduce transmission potential rather than increase it.

Because of these differences, the review argues that public health planning should avoid one-size-fits-all strategies. Surveillance, risk communication, and interventions should be tailored to the likely pathogen mix under local climate regimes.

To reduce risk, the authors recommend “no-regrets” investments that strengthen preparedness across scenarios. These include climate-resilient water, sanitation, and hygiene (WASH) infrastructure; expanded pathogen-specific surveillance to enable early identification of circulating organisms; and vaccination program strengthening where vaccines exist, such as for cholera, rotavirus, polio, hepatitis A, and typhoid.

The paper concludes that no single adaptation strategy will protect against every waterborne disease. Instead, climate resilience efforts must incorporate pathogen-specific responses to environmental change, enabling agencies to better anticipate future outbreak patterns.

Subject of Research: Waterborne diseases and climate change
Article Title: Waterborne diseases and climate change
News Publication Date: Today
Web References: https://www.nature.com/articles/s41579-026-01338-3
References: Nature Reviews Microbiology
Image Credits: Not provided
Keywords: climate change, waterborne disease, epidemiology, WASH, pathogen-specific surveillance, viral transmission, drought, extreme weather

Cryptosporidium protozoan parasites stand out as some of the most virulent waterborne pathogens globally, responsible for severe diarrheal diseases that disproportionately impact young children and immunocompromised adults. The two primary species, Cryptosporidium hominis and Cryptosporidium parvum, exert a deadly toll by causing intense diarrhea that leads to over 50,000 childhood deaths every year. Despite their profound health impact, these parasites linger in the shadows of global research efforts, lacking any approved curative therapies. Moreover, Cryptosporidium’s classification as a CDC Class B bioterrorism agent underscores its potential misuse as a weapon contaminating water supplies, heightening the urgency for dedicated research and medical countermeasures.

In response to this pressing crisis, Professor Cuny’s multi-institutional team brings together leading experts from the University of Houston, University of Washington, and Tufts University. Their collective mission is to harness the latest advancements in enzyme-targeting drug discovery to produce potent, selective inhibitors with the capacity to treat cryptosporidiosis effectively. This strategy pivots on targeting an essential parasite enzyme known as Calcium Dependent Protein Kinase 1 (CDPK1), whose inhibition has been shown to dramatically curtail parasite proliferation, marking it as a validated and highly promising drug target.

CDPK1 is a unique kinase enzyme critical for the survival and replication of Cryptosporidium parasites inside host intestinal cells. Silencing or chemically inhibiting CDPK1 disrupts key signaling pathways that the parasite depends on, resulting in arrested growth and eventual clearance. From a structural biology perspective, CDPK1 displays distinct active site features that differ from homologous human kinases, offering a valuable window for designing selective inhibitors that minimize off-target toxicity. This selectivity is paramount to developing safe therapeutics that spare human cells while dismantling the parasite’s life cycle.

The design philosophy employed by Cuny’s team incorporates not only molecular specificity but also advanced pharmacokinetic considerations to maximize efficacy. A novel aspect of their approach includes engineering drug candidates capable of enterohepatic recycling—a process by which the drug is absorbed through the liver, secreted into the bile, and then reabsorbed in the intestines, effectively prolonging its residence in the gastrointestinal tract. Such recycling enhances the local concentration of the compound where Cryptosporidium wreaks havoc—the intestines—thereby reducing systemic exposure and potential side effects.

This GI-targeting strategy represents a sophisticated leap forward in infectious disease pharmacology, as most antiparasitic drugs are limited by their rapid systemic elimination and insufficient concentrations at the site of infection. By tailoring drugs to persist in the intestinal lumen, Cuny’s team aims to achieve therapeutic concentrations capable of eradicating the parasite without posing undue systemic risk. Moreover, this targeted delivery concept not only holds promise for cryptosporidiosis but could revolutionize treatment paradigms for other gastrointestinal disorders, including inflammatory bowel diseases and certain colonic cancers, by concentrating active agents precisely where they are needed.

Beyond the drug design innovations, collaboration is a cornerstone of this expansive research effort. Ming Hu and Kevin Garey, both endowed professors at the University of Houston, bring expertise in drug discovery and development. Meanwhile, partners from the University of Washington, such as Wesley Van Voorhis, contribute infectious disease insights, and Saul Tzipori from Tufts University offers specialized knowledge in parasitology and pathogenesis. This convergence of multidisciplinary skills ensures that the drug candidates will not only be chemically robust but also biologically validated in relevant disease models.

The urgency of this research cannot be overstated; Cryptosporidium infections remain a leading cause of diarrheal mortality and morbidity in resource-limited and developed regions alike. The absence of effective treatments has perpetuated a cycle of suffering and death, especially among vulnerable populations such as children in low-income countries and people with compromised immune systems. As such, the development of targeted therapeutics represents a fundamental step toward addressing this neglected parasitic disease, with profound implications for global child health and biodefense.

By advancing CDPK1 inhibitors from the laboratory bench toward clinical candidates, the project endeavors to fill a critical void in parasitic disease treatment. Success in this realm would establish a new class of antiparasitic drugs with demonstrated efficacy and safety profiles, ultimately translating into lifesaving medicines that reach the populations in dire need. Furthermore, the scientific paradigm developed through this work will likely energize broader applications across infectious diseases and beyond, signifying a milestone in therapeutic innovation driven by mechanistic enzyme targeting.

Professor Cuny emphasizes that the long-term vision extends beyond individual drug discovery to an integrated approach encompassing pharmacology, toxicology, and clinical translation. The aspiration is to push CDPK1 inhibitors through advanced development stages expeditiously, culminating in treatments that are accessible, affordable, and adaptable to varied healthcare settings globally. This commitment to translational science epitomizes a new frontier in fighting parasitic diseases with precision medicine principles.

This initiative also underscores the significance of federal support from institutions like the National Institute of Allergy and Infectious Diseases, which recognize the critical need for investments in neglected tropical diseases. The nearly $4 million awarded to this effort not only fuels cutting-edge research but also signals a growing acknowledgment of the global health impact posed by parasites like Cryptosporidium. Such backing is essential to accelerating the path from scientific discovery to tangible public health outcomes.

The innovative targeting of CDPK1 as a validated drug target heralds a new era in combating cryptosporidiosis, a disease long overshadowed despite its deadly toll. With the fusion of molecular insight, drug design ingenuity, and collaborative expertise, this pioneering research at the University of Houston stands at the forefront of a transformative approach to tackling devastating parasitic infections that have eluded effective treatment for far too long.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits: University of Houston
Keywords: Parasitic diseases, Infectious diseases, Cryptosporidium, CDPK1, Drug targets, Drug development, Waterborne pathogens, Gastrointestinal infections, Pharmacology, Enzyme inhibitors, Bioterrorism agent